Join to View Full Profile
241 Sunset RdSkillman, NJ 08558
Dr. Hwang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Vanderbilt University Medical CenterFellowship, Infectious Disease, 2005 - 2009- Vanderbilt University Medical CenterResidency, Internal Medicine, 2003 - 2005
West Virginia University School of MedicineClass of 2003
Certifications & Licensure
TN State Medical License 2004 - 2019
Clinical Trials
- HIV Resistance and Treatment Strategies Start of enrollment: 2007 Jan 01
Publications & Presentations
PubMed
- 2 citationsBiotech's role in advancing HIV vaccine development.Roger Tatoud, Christian Brander, Carey Hwang, Jo Kennelly, Shan Lu
Emerging Microbes & Infections. 2024-12-01 - 32 citationsVIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study.Man-Fung Yuen, Young-Suk Lim, Ki Tae Yoon, Tien-Huey Lim, Jeong Heo
The Lancet. Gastroenterology & Hepatology. 2024-12-01 - 7 citationsChronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.Marion G Peters, Man-Fung Yuen, Norah Terrault, John Fry, Pietro Lampertico
Clinical Infectious Diseases. 2024-04-10
Journal Articles
- Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Adults with Human Immun...George J Hanna, Peter Sklar, Kathleen E Squires, Paul E Sax, Carey Hwang, Clinical Infectious Diseases
Press Mentions
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus InfectionSeptember 22nd, 2022- Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver ConferenceJune 27th, 2022
- Vir Biotechnology Announces New Clinical Data from Its Broad Hepatitis B ProgramJune 27th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
